Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| VERO | Venus Concept | $10.33 | $8.90 | 622.38% | 233.7M | $2.7M | $1.39$14.50 |
| LCFY | Locafy | $4.94 | $1.81 | 57.83% | 35.5M | $5.6M | $2.51$13.98 |
| CGTL | Creative Global Technology | $5.82 | $2.01 | 52.76% | 1.1M | $114M | $0.41$6.52 |
| BIYA | Baiya International Group | $6.31 | $1.80 | 39.87% | 18.5M | $5.3M | $3.65$200.00 |
| IBRX | ImmunityBio | $5.43 | $1.48 | 37.47% | 4.1M | $3.9B | $1.83$5.55 |
| NEOV | NeoVolta | $4.59 | $1.16 | 33.82% | 3.3M | $119M | $1.80$6.19 |
| AFJK | Aimei Health Technology | $61.18 | $15.17 | 32.97% | 96.8K | $282M | $6.75$130.37 |
| TNMG | Tnl Mediagene | $3.09 | $0.73 | 30.93% | 15M | $6.0M | $1.94$120.00 |
| JCSE | Je Cleantech | $2.08 | $0.49 | 30.77% | 961.1K | $8.0M | $0.86$2.50 |
| QNCX | Quince Therapeutics | $3.55 | $0.67 | 23.26% | 1.4M | $160M | $0.72$4.55 |
Related Articles
Featured Article
What Has AGX Stock Done for Investors?
Marc Guberti|Dec 21, 2025
This under-the-radar AI stock has crushed the S&P 500.
Here's Why loanDepot Is Reducing Its Mortgage Banking Footprint
Brent Nyitray, CFA|Aug 15, 2022
loanDepot is reorganizing its business to concentrate on what it does best.
Rising Interest Rates Rock loanDepot
Eric Volkman|May 11, 2022
But that's not the only problem the company is facing.
Advertisement
4 Real Estate Trends Smart Investors Are Watching for 2022
Courtney Carlsen|Dec 18, 2021
Real estate lenders may face some headwinds going into 2022.
2 Short-Squeeze Candidates That Could Go Parabolic Soon
George Budwell, PhD|Dec 9, 2021
Cortexyme and Heron Therapeutics are two of the most heavily shorted biopharma stocks right now.
Down 76%: Is Cortexyme Stock a Bargain?
George Budwell, PhD|Oct 28, 2021
The biotech's stock took a big hit after its lead product candidate flunked a key clinical trial.
Cortexyme's Alzheimer's Drug Fails -- 2 Lessons for Investors
Cory Renauer|Oct 28, 2021
Another new drug candidate for the treatment of Alzheimer's disease failed miserably in a clinical trial.
Why Investors Should Be Cautious About loanDepot Despite Record Earnings
Courtney Carlsen|May 19, 2021
The mortgage lender posted strong growth year over year, but headwinds from rising interest rates could pose a problem for the industry.
3 Best Emerging Growth Stocks to Buy Now
Zhiyuan Sun|Mar 26, 2021
Searching for stocks with above-average growth potential? Look no further.
Is loanDepot a Buy?
Brent Nyitray, CFA|Mar 9, 2021
loanDepot's mello technology may be the key to the company's success.
